GlobeNewswire by notified

Investeringsforeningen Carnegie Wealth Management – Prospekt

Del

Opdateret prospekt for Investeringsforeningen Carnegie Wealth Management offentliggøres dags dato.

Prospektet er opdateret med nøgletal for 2023. Herudover er der foretaget generelle præciseringer, heriblandt i afsnittet for henholdsvis administration og depot.

Prospektet er vedhæftet og kan også findes på foreningens hjemmeside www.carnegie.dk/carnegie-invest.

Eventuelle spørgsmål kan rettes til undertegnede på telefon 3814 6600.

Med venlig hilsen

Niels Erik Eberhard
Direktør

Vedhæftet fil

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

Tryg A/S – Interim report Q1 202417.4.2024 07:30:00 CEST | Press release

Tryg’s Supervisory Board has today approved the Q1 2024 interim report. Tryg reported an insurance service result of DKK 1,275m (DKK 1,474m) and a combined ratio of 86.6 (84.0) in Q1 2024, adversely impacted by more than DKK 180m higher than normal weather and large claims level. The underlying claims ratio for the Group improved by 50bps, whilst the Private segment displayed a deterioration of 50bps driven by an increase in motor claims frequency. Tryg reported a top-line growth of 4.8% primarily driven by price increases to offset inflationary pressures. Synergies from the RSA Scandinavia acquisition were DKK 43m in the quarter and DKK 754m accumulated. The investment result was DKK 117m (DKK 167m) mainly impacted by positive returns from equities and covered bonds. Pre-tax profit was DKK 1,007m (DKK 1,187m) and profit after tax was DKK 776m. Quarterly dividend of DKK 1.95 (DKK 1.85) per share an increase of more than 5%, solvency ratio of 191 supportive of future shareholders' retur

Tryg A/S – 1. kvartals rapport 202417.4.2024 07:30:00 CEST | pressemeddelelse

Trygs bestyrelse har i dag godkendt 1. kvartals rapport for 2024 Tryg rapporterede et insurance service result på 1.275 mio. DKK (1.474 mio. DKK) og en combined ratio på 86,6 (84,0) i 1. kvartal 2024 påvirket negativt af højere end normalt vejr- og storskader niveau for mere end 180 mio. DKK. Den underliggende erstatningsprocent for Tryg Koncernen blev forbedret med 0,5 procentpoint, hvorimod Privat havde en forværring i den underliggende erstatningsprocent på 0,5 procentpoint påvirket af en stigning i frekvensen for motor skader. Tryg rapporterede en vækst på 4,8% i lokal valuta drevet af prisjusteringer for at imødegå effekten fra skadesinflationen. Synergier fra RSA Skandinavien transaktionen udgjorde 43 mio. DKK og 754 mio. DKK akkumuleret. Investeringsresultatet udgjorde 117 mio. DKK. (167 mio. DKK) og var primært påvirket af positive afkast på aktier og realkreditobligationer. Resultatet før skat udgjorde 1.007 mio. DKK (1.187 mio. DKK) og 776 mio. DKK efter skat. Udbyttet for kv

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis17.4.2024 07:15:00 CEST | Press release

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1 Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy outcomes such as annualized relapse rate and MRI lesion activity in both analyses1,2 Treatment with Kesimpta for up to six years continues to be well tolerated with consistent safety outcomes, supporting the favorable benefit-risk profile of Kesimpta in RMS2 Basel, April 17, 2024 – Novartis today announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® (ofatumumab) treatment for up to six years in recently diagnosed – defined as s

Idorsia publishes a Financial Status required for an upcoming bondholder meeting17.4.2024 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholders Allschwil, Switzerland – April 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the following link: http://www.idorsia.com/investors/financial-information Idorsia continues to engage with bondholders on options and terms regarding the repayment of the convertible bond maturing on July 17, 2024 (ISIN: CH0426820350). As a result, the bondholder meeting initially contemplated for April 30, 2024, is expected to take place shortly thereafter. André C. Muller, Chief Financial Officer, commented: “We have had many interactions with our bondholders in the past week. We are finalizing our pr

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis17.4.2024 07:00:00 CEST | Press release

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS Paris, April 17, 2024. Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis. These data will be presented today at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, Colorado, US. Results from the 12-week double-blind study period were previously published in The New England Journal of Medicine. Patrick Vermersch, MD, PhD University of Lille,

HiddenA line styled icon from Orion Icon Library.Eye